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Abstract
Aim To assess the health-related outcomes of hypoglycaemia for people with diabetes admitted to hospital; specifically,
hospital length of stay and mortality.
Methods We conducted a systematic review and meta-analysis of studies relating to hypoglycaemia (< 4 mmol/l) for
hospitalized adults (≥ 16 years) with diabetes reporting the primary outcomes of interest, hospital length of stay or
mortality. Final papers for inclusion were reviewed in duplicate and the adjusted results of each were pooled, using a
random effects model then undergoing further prespecified subgroup analysis.
Results In total, 15 studies were included in the meta-analysis. The pooled mean difference in length of stay for ward-
based inpatients exposed to hypoglycaemia was 4.1 days longer [95% confidence interval (CI) 2.36 to 5.79; I² = 99%]
compared with those without hypoglycaemia. This association remained robust across the pre-specified subgroup
analyses. The pooled relative risk (RR) of in-hospital mortality was greater for those exposed to hypoglycaemia (RR
2.09, 95% CI 1.64 to 2.67; I² = 94%, n = 7 studies) but not in intensive care unit mortality (RR 0.75, 95% CI 0.49 to
1.16; I² =0%, n = 2 studies).
Conclusion There is an association between inpatient hypoglycaemia and longer length of stay and greater in-hospital
mortality. Studies examining this association were heterogenous in terms of both clinical populations and effect size, but
the overall direction of the association was consistent. Therefore, glucose concentration should be considered a potential
tool to aid the identification of inpatients at risk of poor health-related outcomes.
Diabet. Med. 36, 1349–1359 (2019)
Introduction
One in six NHS hospitals beds, across all specialties, is
occupiedby someonewithdiabetes [1].TheNational Inpatient
Diabetes Audit reported that among 15 774 hospitalized
people with diabetes in over 200 hospitals, good glycaemic
control was achieved on fewer than half of their inpatient days
[2]. Additionally, ~ 20% of hospitalized people with insulin-
treated diabetes experience one or more episodes of hypogly-
caemia, with 8%of episodes classed as severe.Hypoglycaemia
is also a common occurrence in critically unwell people
without diabetes.
In 2017, the International Hypoglycaemia Study Group
defined hypoglycaemia in clinical trials as a glucose level of
< 3.0 mmol/l, with 3.0–3.9 mmol/l redefined as an alert
level. They also reported that, in people with diabetes, the
counter-regulatory response to hypoglycaemia will differ
dependent on the individual’s glucose control [3]. It remains
common practice, however, for a glucose level of < 4 mmol/l
to trigger hypoglycaemia treatments in hospital [4].
Several factors are associated with the increased risk of
hypoglycaemia for hospitalized people with diabetes. These
may relate to changes in physiology, pharmacological treat-
ments or the environment, and inappropriate diabetes
management. Physiological and pharmacological factors
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include acute kidney injury, liver failure, sepsis, reduction in
medications known to increase glucose levels, such as
corticosteroids, and polypharmacy. Changes in the environ-
ment increase hypoglycaemia risk through factors such as the
limited availability of food, long fasting time from evening
meal to breakfast and unexpected deviations in hospital care.
Inappropriate diabetes management includes overuse of
variable rate intravenous insulin infusion, and errors in
prescribing and drug administration [5,6]. Despite the
potential morbidity and known risk factors for hypogly-
caemia [7], measures to counteract these risks in hospital are
not routinely taken.
Extant studies examining the effect of hypoglycaemia in
peoplewithdiabeteswhoarehospitalizedhavegenerally found
negative clinical outcomes, but with estimates of varying
precision and from a range of clinical populations [8–24].
Therefore,weperformedasystematicreviewandmeta-analysis
to investigate the extent towhichhypoglycaemia inpeoplewho
are hospitalized influences length of stay and mortality. This
review focuses on people with diabetes who were exposed to
hypoglycaemia during their hospital admission.
Research design and methods
In accordance with our published protocol (PROSPERO
CRD42017062611), we performed a systematic review and
meta-analysis. Studies were included if they met all the
following criteria: participants were aged ≥ 16 years and had
a diagnosis of diabetes (or data from study participants with
diabetes could be extracted separately); the exposed group
experienced hypoglycaemia (< 4.0 mmol/l or equivalent
hospital coding) and was compared against a control group
without hypoglycaemia; and the study outcomes included
one or both of the primary outcomes for this systematic
review (length of stay or mortality). Papers were excluded if
study samples included participants who were admitted with
hypoglycaemia, paediatric or pregnant populations, were
based in a primary care or emergency department setting, or
if the study did not report either outcome of interest or a
qualitative research design was used. Reporting is in accor-
dance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines [25]. A
multidisciplinary panel of academic and clinical experts was
formed. This panel determined the review protocol and
contributed to various aspects of the review.
Data sources and search strategy
The following databases were searched for all available
dates: MEDLINE (Ovid), Embase, CINAHL Complete,
Scopus and Web of Science, ClinicalTrials.gov, UK Clinical
trials, gateway (current and archived), Open Grey, NHS
Evidence, ProQuest UK/Ireland, ProQuest International,
Prospero and the Cochrane databases. These databases were
chosen as they hold papers on healthcare-related research
from various professional perspectives [26,27]. The first
database search was undertaken on 28 June 2017 and an
updated search on MEDLINE (Ovid), Embase, CINAHL
Complete, Scopus and Web of Science was undertaken on 6
June 2018 using the same search terms. Details of the search
terms used are provided in Appendix S1. Both searches were
undertaken through the website of the host university using
the same search strategy and databases [28].
The MEDLINE (Ovid), Embase, CINAHL Complete,
Scopus and Web of Science searches were carried out by
the lead author and independently by an information
specialist on the same day. All searches were limited to the
English language. Reference management was carried out
using Mendeley.
Study selection
All titles and abstracts were assessed independently and in
duplicate to identify articles requiring full-text review against
the predefined inclusion criteria. Papers found through grey
literature searching were assessed by the first author (AL).
Eligible citations identified after title and abstract review
were all then full-text reviewed by two people. Reasons for
exclusion were recorded. Any disagreements between review-
ers were resolved by consensus and in consultation with the
expert panel. Review of the reference lists of the citations for
full-text review was also undertaken (by AL) to identify
additional relevant papers.
Data extraction
Data from included studies were extracted using prespecified
data extraction forms. Extracted data included study demo-
graphics and design, in-hospital location, diagnostic criteria
for hypoglycaemia, sample size and outcomes reported.
Where reported, adjusted findings were used. Hypoglycaemia
definitions were grouped for analyses in line with the
What’s new?
• Heterogeneity of inpatient populations and definitions
of hypoglycaemia are a significant challenge in synthe-
sizing evidence from previously published studies.
• Hypoglycaemia events, including those considered non-
serious, are associated with an increased length of
hospital stay and increased risk of inpatient mortality.
• Inpatient hypoglycaemia is a marker for clinical dete-
rioration and potential increased risk for adverse
outcomes.
• Glucose measurements could aid the identification of
those at risk of poor health-related outcomes.
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consensus recommendation made by the international hypo-
glycaemic group (non-serious: ≥ 3.0 and < 4.0 mmol/l;
serious: < 3.0 mmol/l) [3]. Authors were contacted if studies
had missing data or inconsistencies. If the data could not be
retrieved or queries resolved, the citation was excluded from
the meta-analysis. The standard deviation was not reported
for two studies and was therefore imputed based on the mean
of the studies reporting a similar mean. These publications
were removed during sensitivity analysis [29]. Record man-
agement was carried out using Microsoft Excel.
Data synthesis
The primary outcome was hospital length of stay and all-
cause mortality. Data were pooled into relative risk (RRs) or
mean difference with 95% confidence intervals (CI) for
dichotomous and continuous outcomes, respectively. Meta-
analysis was performed using random effects models, apply-
ing the DerSimonian and Laird statistical method [30].
A prespecified analysis was undertaken stratified by hospi-
tal location (ICU, medical wards, speciality areas or not
specified), research methodology, hypoglycaemia definition,
removal of outliers, removal of poor-quality papers, prospec-
tive cohort study design and time point of reported outcomes
(in hospital mortality vs. post discharge mortality). Statistical
heterogeneity was assessed through the I2 test for heterogene-
ity. Regression tests for analysis and publication bias were not
completed because there were fewer than 10 papers overall for
publication bias or per covariate in meta-regression tests
[31,32]. Small study effect was examined using funnel plots.
Analysis was conducted using RevMan version 5.3.
Quality assessment
Studies were reviewed to determine whether the cohort
observed was representative of the study population and
whether there was risk of bias in the recruitment process or
identification of the exposure to hypoglycaemia [33]. Bias
and methodological assessment was completed by two
reviewers (AL and CB) using an adapted version of the
Newcastle–Ottawa scale [34]. The Newcastle–Ottawa scale
rates eight items relevant to cohort study design: represen-
tativeness of cohort, selection of non-exposed cohort, ascer-
tainment of exposure, demonstration of no exposure at
admission, comparability of cohorts, assessment of outcome,
sufficient length of follow-up and adequacy of follow-up.
Each study was then given a total score equating to a rating
of poor, fair or good quality. The results were compared, and
disagreements resolved through consensus [35].
Results
A total of 10 374 papers were identified, 8401 through
database searches and 1973 from other sources. Once
duplicates had been removed, 7290 papers remained and
were reviewed by title and abstract for eligibility. Some 7195
studies were excluded based on the inclusion criteria, leaving
95 for full review. A further 72 studies were excluded
following full-text review, leaving 23 for inclusion. Another
six were excluded as the data required for analysis could not
be extracted. For length of stay, the reason for exclusion was
typically because a mean and standard deviation could not be
extracted. For mortality, the most common reason for
exclusion was because data for people with diabetes could
not be separated from data for those without. Of the 17
remaining studies, three papers were by the same author
Krinsley [8–10] and a combined data set was kindly provided
by the lead author to prevent duplication of analysis. This
resulted in 15 eligible studies [8–24] (Fig. 1).
Study characteristics
The characteristics of the 15 included studies are shown in
Table 1. The hospital locations included a general ward
(n = 6), ICU (n = 4), location not specified (n = 4) and a
specialty cardiacward (n = 1). Studieswerepublishedbetween
2009 and 2016 and the designs included observational studies
(n = 9), sub-analysis of a randomized controlled trial (RCT)
(n = 3), nested cohort within a RCT (n = 1), sub-analysis of a
cross-sectional study (n = 1) and a case-controlled study
(n = 1). Geographical locations included the USA (n = 7),
UK (n = 2), and one study each from Spain, the Netherlands,
Saudi Arabia, Singapore, Italy and Sweden. Most were single-
centre studies with amean sample size of 32 788 (range 288 to
300 020),with ameanof11 425peoplewithdiabetes exposed
to hypoglycaemia. All studies adjusted for age, sex and
comorbidities. Eight studies adjusted for at least one other
patient demographic such as socio-economic status, ethnicity,
health insurance status or education level.
Quality assessment
Of the 15 studies reviewed, the ascertainment of hypogly-
caemia exposure and selection of the non-exposed cohort
were clearly reported. Many studies that would otherwise
have scored highly were rated poor because it was not
explicitly stated whether the population was not admitted
with hypoglycaemia or the exact follow-up duration. We
recognize that this is likely due tomany of the included studies
not being published with their suitability for subsequent
systematic review in mind. All papers reported the selection of
the non-exposed cohort, method of ascertainment of exposure
and used record linkage for assessment of outcome.
Association between inpatient hypoglycaemia and length of
hospital stay outside intensive care
The overall pooled mean difference of the nine studies
reporting length of stay outcomes [11–14,18–,20,22,23]
suggests that people with diabetes, who experienced at least
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one episode of hypoglycaemia during their admission, had an
increased length of hospital stay by a mean of 4.08 days
(95% CI 2.36 to 5.79; n = 9 studies) (Fig. 2a). This
statistically significant association held for all subgroup
analyses. Although the statistical heterogeneity was very high
(I² = 99%), all included studies demonstrated that hypogly-
caemia was associated with increased length of stay even
when only the five papers reporting non-serious definitions of
hypoglycaemia were included (4.37 days, 95% CI 2.13 to
6.61; I² = 98%, n = 5 studies) [13,19,20,22,23].
Association between inpatient hypoglycaemia and all-cause
mortality by mortality time point
The overall pooled relative risk (RR) of in-hospital mortality
from the ward-based or location not specified studies
[11,13,18,20,21,23,24] was 1.90 (95% CI 1.51 to 2.39; I²
= 93%, n = 7 studies) suggesting that the risk of in-hospital
mortality is nearly doubled for people with diabetes exposed
to hypoglycaemia. This remained significant when analysis
was restricted to the two studies reporting 90-day and post-
discharge mortality (RR 1.26, 95% CI 1.08 to 1.47; I² = 0%,
n = 2 studies) [15,24]. However, there was no association
found for the overall pooled RR of the two studies reporting
ICU mortality (RR 0.75, 95% CI 0.49 to 1.16; I² = 0%, n = 2
studies) [16,17].
The in-hospital mortality results were obtained in the
presence of substantial statistical heterogeneity (Fig. 2b).
This heterogeneity was reduced, and the risk further
increased when only in-hospital mortality and non-serious
hypoglycaemia definitions were included (RR 2.15, 95% CI
1.98 to 2.33; I² = 0%, n = 5 studies) [8–10,13,20,21,23]
(Table 2). Of the papers looking at the association with a
serious hypoglycaemia episode (< 3 mmol/l), only one
reported in-hospital mortality [18]. Throughout the sub-
group analyses, the association between hypoglycaemia and
mortality remained statistically significant outside ICU mor-
tality.
Small study effect
The studies reporting length of stay did not take the inverse
funnel shape expected suggesting the potential presence of
publication bias (Fig. S1). Although publication bias is less
problematic in the mortality analyses, there is some potential
for publication bias within the in-hospital mortality sub-
group (Fig. S2).
Discussion
This is the first meta-analysis pooling the reported data on
the effect of inpatient hypoglycaemia exposure on length of
FIGURE 1 PRISMA flow chart.
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hospital stay and all-cause mortality. We found an overall
positive association between hypoglycaemia and both
increased length of stay and in-hospital mortality outside
ICU settings. No significant association was found between
ICU mortality and hypoglycaemia. This nonsignificant find-
ing could reflect the frequency of blood glucose monitoring,
and more responsive treatment of hypoglycaemia in ICU
compared with the general ward setting. Additionally, the
population treated within an ICU setting are likely to be
fundamentally different from those cared for on a hospital
ward. None of the included studies within the ICU setting
reported length of stay.
The strengths of this review include a comprehensive
search strategy, designed and tested with an information
specialist, reviewers’ specialist diabetes knowledge and
inclusion of experienced systematic review researchers.
(a)
(b)
FIGURE 2 Forest plots of (a) mortality and (b) length of stay.
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Limitations include the poor-quality rating for some studies,
the presence of substantial clinical and statistical hetero-
geneity, and the inability to be sure that people were not
admitted primarily for diabetes-related acute events other
than hypoglycaemia (diabetic ketoacidosis and hypergly-
caemic hyperosmolar state). We were also unable to elimi-
nate language bias or control for different methods of glucose
measurements (capillary vs. venous), glycaemic variability,
causes of hypoglycaemia and in-hospital hypoglycaemia
management.
Despite these limitations, there are good reasons to be
confident in these findings. They are supported by publica-
tions that were considered for inclusion but not eligible for
the meta-analysis [36–40]. Furthermore, our findings support
the statements from the American Diabetes Association [41]
and the Joint British Diabetes Societies [4] guidelines who
report that hypoglycaemia increases risks among people with
diabetes admitted to hospital.
This review has demonstrated some of the complexities
and challenges associated with diabetes inpatient research.
The main areas of methodological and clinical heterogeneity
were the varying definitions for hypoglycaemia, different
hospital locations and different research methodologies used.
We attempted to address these as robustly as possible
through pre-specified sensitivity testing. During acute inpa-
tient hospital care, people from a variety of backgrounds are
brought together in a hospital environment, with various
presenting conditions ranging from routine surgery (e.g.
cataracts, varicose vein) to life-threatening emergencies (e.g.
aortic aneurysm, peritonitis). Controlling for heterogeneity
among this diverse population is not possible. Even within
hospital location and diabetes type, individual health needs
and disease severity vary greatly. This is likely to be a
contributing factor to the substantial statistical heterogene-
ity. However, because the positive association between
hypoglycaemia exposure and increased length of stay was
largely consistent, we believe that the statistical heterogeneity
represents variance in magnitude rather than the direction of
the overall association.
Papers included within this review were published before
the new biochemical definition of hypoglycaemia in clinical
trials was published in 2017 [3]. As result, many of the
studies included in their definitions of hypoglycaemia events
that would now be considered an ‘alert level’. We attempted
to address this through subgroup analysis. Contrary to
expectations, the association between non-serious hypogly-
caemia and length of hospital stay and in-hospital mortality
remained. However, the definition of non-serious hypogly-
caemia used in some studies may have included those
exposed to serious hypoglycaemia as this was not an
exclusion [8–10,13,15,19–,23].
Whether hypoglycaemia has a causal effect or is a
marker of ill health is unclear and outside the scope of
this review. One theory for the finding that hypogly-
caemia at alert levels (≥ 3.0 and ≤ 4.0 mmol/l) within the
hospital setting is associated with increased risk, is that
the early associated counterregulatory response to hypo-
glycaemia could be harmful in acutely unwell people with
diabetes. Catecholamine release in response to hypogly-
caemia is less well tolerated by older patients and those
with cardiac morbidities. In addition, hypoglycaemia
increases both platelet aggregation and prothrombotic
Table 2 Summary of subgroup analysis for the effect of inpatient hypoglycaemia on length of stay and mortality
Category Studies included (N) Result* I² (%)
Subgroup analysis of the effect of hypoglycaemia on length of stay
All studies 9 4.08 (2.36 to 5.79) 99
Removal of papers rated as poor quality 4 3.59 (0.80 to 7.62) 99
Removal of non-cohort studies 7 4.15 (2.11 to 6.19) 99
Removal of studies with imputed standard deviation 6 3.62 (2.09 to 5.14) 98
General ward location only 6 3.24 (1.01 to 5.47) 97
Hospital location not specified only 4 5.08 (2.14 to 8.02) 100
Inclusion of non-serious hypoglycaemia definitions only 5 4.37 (2.13 to 6.61) 98
Inclusion of serious hypoglycaemia definitions only 2 2.87 (-0.36 to 6.10) 98
General ward areas only and removal of outliers 8 2.14 (1.30 to 2.99) 70
General ward location and removal of papers rated as poor quality 2 1.63 (0.87 to 2.40) 67
Hospital location not specified, and removal of papers rated as poor quality 2 5.58 (3.55 to 7.62) 97
Subgroup analysis of the effect of hypoglycaemia on mortality
All studies 11 1.69 (1.40 to 2.03) 92
Removal of papers rated as poor quality 5 1.81 (1.36 to 2.42) 90
Removal of non-cohort studies 4 1.62 (1.16 to 2.26) 95
Removal of studies with imputed data 9 1.57 (1.29 to 1.91) 87
In-hospital mortality only 7 2.09 (1.64 to 2.67) 94
In-hospital mortality and non-serious hypoglycaemia definition 5 2.15 (1.98 to 2.33) 0
Intensive care unit mortality only (all used serious hypo definitions) 2 0.75 (0.49 to 1.16) 0
90-day and post discharge mortality only 2 1.26 (1.08 to 1.47) 0
*Mean difference in length of stay in days or risk ratio (95% confidence interval).
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factors, which could also contribute to increased harm
[42,43]. Although the association may not be causal, this
review suggests it could be a marker for ill health or
worse outcomes.
Hypoglycaemia and fear of potential hypoglycaemia
remain a major barrier for healthcare professionals when
supporting people with diabetes in hospital to achieve
optimal glucose control [44–46]. Inadequate education and
clinical knowledge about the risks associated with and
strategies for prevention of hypoglycaemia in hospitalized
people, may contribute to the suboptimal inpatient diabetes
management documented by successive National Inpatient
Diabetes Audits [1]. This review supports the need to be
cautious in balancing the risks of hypoglycaemia with
optimal hyperglycaemia management. To achieve better
inpatient diabetes control, the gap between evidenced-based
medicine and clinical practice needs to be considered
carefully. Consideration could be given to including hypo-
glycaemia on early warning systems, such as the national
early warning score to raise awareness and prompt a timely
review of glucose management, or document glucose along-
side other vital signs used to detect clinical deterioration
[47,48].
More research is required to gain a deeper understanding
of the barriers to, and potential strategies for, providing
optimal inpatient diabetes care. More work is needed to
update non-specialist healthcare professionals to implement
best care for people with diabetes while admitted to hospital
and support increasingly time pressured front-line hospital
staff to have timely access to evidence.
Funding sources
A. L. conducts independent research supported by the
National Institute for Health Research (MRES-2015-03-
025-204). The views expressed in this publication are those
of the authors and not necessarily those of the NHS, the
National Institute for Health Research or the UK Depart-
ment of Health.
Competing interests
None disclosed
Acknowledgements
Many thanks for the contributions made to the project by
Karen Callaby, Alison Jeffs, Makylah Lavender, Eirini
Pizirtzidou, Leanne Jenkins and Dr Veronica Phillips.
References
1 NaDIA Advisory Group. National Diabetes Inpatient Audit Eng-
land and Wales, 2017. Available at https://digital.nhs.uk/catalogue/
PUB30248 Last accessed 16 April 2018.
2 NaDIA Advisory Group. National Diabetes Inpatient Audit Eng-
land and Wales, 2016. Available at http://content.digital.nhs.uk/ca
talogue/PUB23539/nati-diab-inp-audi-16-rep.pdf Last accessed 11
April 2017.
3 International Hypoglycaemia Study Group. Glucose concentrations
of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical
trials: a Joint Position Statement of the American Diabetes
Association and the European Association for the Study of
Diabetes. Diabetes Care 2017; 40: 155–157.
4 Joint British Diabetes Societies for Inpatient Care. The Hospital
Management of Hypoglycaemia in Adults with Diabetes Mellitus,
3rd edition. Available at https://abcd.care/sites/abcd.care/files/
resources/20180508_JBDS_HypoGuideline_Revised_v2.pdf Last
accessed 12 August 2018.
5 Smith WD, Winterstein AG, Johns T, Rosenberg E, Sauer BC.
Causes of hyperglycaemia and hypoglycaemia in adult inpatients.
Am J Health-Syst Pharm 2005; 62: 714–719.
6 Hulkower RD, Pollack RM, Zonszein J. Understanding hypo-
glycemia in hospitalized patients. Diabetes Manage 2014; 4: 165–
176.
7 Frier BM. Hypoglycaemia in diabetes mellitus: epidemiology and
clinical implications. Nat Rev Endocrinol 2014; 10: 711–722.
8 Krinsley JS, Grover A. Severe hypoglycaemia in critically ill
patients: risk factors and outcomes. Crit Care Med 2007; 35:
2262–2267.
9 Krinsley JS, Schultz MJ, Spronk PE, Harmsen RE, Bram Houck-
geest FV, Van Der Sluijs JP et al. Mild hypoglycemia is indepen-
dently associated with increased mortality in the critically ill.
Critical Care 2011; 15: 1–10.
10 Krinsley JS, Maurer P, Holewinski S, Hayes R, McComsey D,
Umpierrez GE et al. Glucose control, diabetes status, and mortality
in critically ill patients: the continuum from intensive care unit
admission to hospital discharge. Mayo Clin Proc 2017; 92: 1019–
1029.
11 Gomez-Huelgas R, Guijarro-Merino R, Zapatero A, Barba R,
Guijarro-Contreras A, Tinahones F et al. The frequency and impact
of hypoglycaemia among hospitalized patients with diabetes: a
population-based study. J Diabetes Complicat 2015; 29: 1050–
1055.
12 McEwan P, Thorsted BL, Wolden M, Jacobsen J, Evans M.
Healthcare resource implications of hypoglycemia-related hospital
admissions and inpatient hypoglycaemia: retrospective record-
linked cohort studies in England. BMJ Open Diabetes Res Care
2015; 3: 1–6.
13 Curkendall SM, Natoli JL, Alexander CM, Nathanson BH, Haidar
T, Dubois RW. Economic and clinical impact of inpatient diabetic
hypoglycaemia. Endocrin Pract 2009; 15: 302–312.
14 Geremakis CM. Metabolic adverse events: patient risk factors, cost
and implications for patient safety. PhD thesis, St Louis University,
2013.
15 NICE-SUGAR Study Investigators. Hypoglycemia and risk of
death in critically ill patients. N Engl J Med 2012; 367: 1108–
1118.
16 Sechterberger MK, Bosman RJ, Oudemans-van Straaten HM,
Siegelaar SE, Hermanides J, Hoekstra JBL et al. The effect of
diabetes mellitus on the association between measures of gylcaemic
control and ICU mortality: a retrospective cohort study. Crit Care
2013; 17: 1–10.
17 Arabi YM, Tamim HM, Rishu AH. Hypoglycaemia with intensive
insulin therapy in critically ill patients: Predisposing factors and
association with mortality. Crit Care Med 2009; 37: 2536–2542.
18 Turchin A, Matheny ME, Shubina M, Scanlon J, Greenwood B,
Pendergrass ML. Hypoglycaemia and clinical outcomes in patients
with diabetes hospitalized in the general ward. Diabetes Care
2009; 32: 1153–1157.
1358
ª 2019 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK
DIABETICMedicine Effect of inpatient hypoglycaemia  A. Lake et al.
19 Ong KY, Kwan YH, Tay HC, Tan DS, Chang JY. Prevalence of
dysglycaemia events among inpatients with diabetes mellitus: a
Singaporean perspective. Singapore Med J 2015; 56: 393–400.
20 Borzi V, Frasson S, Gussoni G, Di Lillo M, Gerloni R, Augello G
et al. Risk factors for hypoglycaemia in patients with type 2
diabetes, hospitalized in internal medicine wards: Findings from
the FADOI-DIAMOND study. Diabetes Res Clin Pract 2016; 115:
24–30.
21 Nirantharakumar K, Marshall T, Kennedy A, Narendran P,
Hemming K, Coleman JJ. Hypoglycaemia is associated with
increased length of stay and mortality in people with diabetes
who are hospitalized. Diabet Med 2012; 29: e445–e448.
22 Kim Y, Rajan KB, Sims SA, Wroblewski KE, Reutrakul S. Impact
of glycemic variability and hypoglycaemia on adverse hospital
outcomes in non-critically ill patients. Diabetes Res Clin Pract
2014; 103: 437–443.
23 Boucai L, Southern WM, Zonszein J. Hypoglycemia-associated
mortality is not drug-associated but linked to comorbidities. Am J
Med 2011; 124: 1028–1035.
24 Melbin LG, Malmberg K, Waldenstrom A, Wedel H, Ryden L.
Prognostic implications of hypoglycaemia episodes during hospi-
talisation for myocardial infarction in patients with type 2 diabetes:
a report from the DIGAMI 2 trial. Heart 2008; 95: 721–727.
25 Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group.
Preferred reporting items for systematic reviews and meta-analyses:
the PRISMA statement. Ann Intern Med 2009; 151: 264–269.
26 Bin Ali N, Usman M. Reliability of search in systematic reviews:
towards a quality assessment framework for the automated-search
strategy. Inform Softw Technol 2018; 99: 133–147.
27 Relevo R. Effective search strategies for systematic reviews of
medical tests. In: Chang SM, Matchar DB, Smetana GW, Umscheid
CA (eds), Methods Guide for Medical Test Reviews. Rockville,
MD: Agency for Healthcare Research and Quality, 2012. Available
at https://www.ncbi.nlm.nih.gov/books/NBK98242/ Last accessed
18 July 2018.
28 Yoshii A, Plaut DA, McGraw KA, Anderson MJ, Wellik KE.
Analysis of the reporting of search strategies in Cochrane system-
atic reviews. J Med Library Assoc 2009; 97: 21–29.
29 Higgins JPT, Deeks JJ, Altman DG. Special topics in statistics. In:
Higgins JPT, Green S (eds), Cochrane Handbook for Systematic
Reviews of Interventions, Version 5.1.0 [updated March 2011].
The Cochrane Collaboration, 2011. Available at www.handbook.c
ochrane.org Last accessed 27 August 2019.
30 Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews
of Interventions. Chichester: Wiley-Blackwell, 2008.
31 Sterne JAC, Egger M, Moher D. Addressing reporting biases. In:
Higgins JPT, Green S (eds), Cochrane Handbook for Systematic
Reviews of Interventions, Version 5.1.0 [updated March 2011].
The Cochrane Collaboration, 2011. Available at www.handbook.c
ochrane.org Last accessed 18 August 2018.
32 Borenstein M, Hedges LV, Higgins JPT. Introduction to Meta-
Analysis. Hoboken, NJ: Wiley, 2011.
33 Harrison JK, Reid J, Quinn TJ, Shenkin SD. Using quality
assessment tools to critically appraise ageing research: a guide for
clinicians. Age Ageing 2017; 46: 359–365.
34 Reeves BC, Deeks JJ, Higgins JPT, Wells GA. Including non-
randomized studies. In: Higgins JPT, Green S (eds), Cochrane
Handbook for Systematic Reviews of Interventions, Version 5.1.0
[updated March 2011]. The Cochrane Collaboration, 2011.
Available at www.handbook.cochrane.org Last accessed 14 July
2018.
35 Holly C, Porter S. Appraising and extracting data. In: Jadotte Y,
Holly C, Salmond S (eds), Workbook for Systematic Review.
Philadelphia, PA: Lippincott, 2016: 20–26.
36 Jones GC, Timmons JG, Cunningham SG, Cleland SJ, Sainsbury
CAR. Hypoglycemia and clinical outcomes in hospitalized patients
with diabetes: does association with adverse outcomes remain
when number of glucose tests performed is accounted for? J
Diabetes Sci Technol 2017; 11: 720–723.
37 Egi M, Krinsley JS, Maurer P, Amin DN, Kanazawa T, Ghandi S
et al. Pre-morbid glycemic control modifies the interaction between
acute hypoglycaemia and mortality. Intensive Care Med 2016; 42:
562–571.
38 Plummer MP, Finnis ME, Horsfall M, Ly M, Kar P, Ali
Abdelhamid Y et al. Prior exposure to hyperglycaemia attenuates
the relationship between glycaemic variability during critical illness
and mortality. Crit Care Resusc 2016; 18: 189–197.
39 Akirov A, Grossman A, Shochat T, Shimon I. Mortality among
hospitalized patients with hypoglycemia: insulin related and
noninsulin related. J Clin Endocrin Metab 2017; 102: 416–424.
40 Takeishi S, Mori A, Hachiya H, Yumura T, Ito S, Shibuya T et al.
Hypoglycemia and glycemic variability are associated with mor-
tality in non-intensive care unit hospitalized infectious disease
patients with diabetes mellitus. J Diabetes Invest 2015; 7: 1–7.
41 American Diabetes Association. Diabetes care in the hospital.
Diabetes Care 2017; 40: 120–127.
42 Wright RJ and Frier BM. Vascular disease and diabetes: is
hypoglycaemia an aggravating factor? Diabetes Metab Res Rev
2008; 24: 353–363.
43 Chow E, Iqbal A, Walkinshaw E, Phoenix F, Macdonald IA, Storey
RF et al. Prolonged prothrombotic effects of antecedent hypo-
glycemia in individuals with type 2 diabetes. Diabetes Care 2018;
41: 2625–2633.
44 Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to
insulin therapy and approaches to overcoming them. Diabetes
Obes Metab 2018; 20: 488–496.
45 Cook CB, Jameson KA, Hartsell ZC, Boyle ME, Leonhardi BJ,
Farquhar-Snow M et al. Beliefs about hospital diabetes and
perceived barriers to glucose management among inpatient
midlevel practitioners. Diabetes Educ 2008; 34: 75–83.
46 Wild D, Maltzahn RV, Brohan E, Christensen T, Clauson P,
Gonder-Frederick L. A critical review of the literature on fear of
hypoglycemia in diabetes: implications for diabetes management
and patient education. Patient Educ Couns 2007; 68: 10–15.
47 Downey CL, Tahir W, Randell R, Brown JM, Jayne DG. Strengths
and limitations of early warning scores: a systematic review and
narrative synthesis. Int J Nurs Stud 2017; 76: 106–119.
48 Kolic I, Smiley C, McCartney S, Perkins Z, Taylor A. Factors
affecting response to National Early Warning Score (NEWS).
Resuscitation 2015; 90: 85–90.
Supporting Information
Additional supporting information may be found online in
the Supporting Information section at the end of the article.
Appendix S1. Final search strategy used in MEDLINE.
Figure S1. Hypoglycaemia and length of stay funnel plot.
Figure S2. Hypoglycaemia and mortality funnel plot.
ª 2019 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK 1359
Systematic Review or Meta-analysis DIABETICMedicine
